Amended recombinant cells (ARCs™) expressing bovine IFN-γ: An economical and highly effective adjuvant system

Vaccine

Volumn 27, Issue 9, 2009, Pages 1377-1385

  Gaertner, Frank H ^a   Babiuk, Lorne A ^b   Mutwiri, George ^b   Armstrong, Janna M ^c   Griebel, Philip J ^b  

^a DOW CHEMICAL COMPANY   (United States)

^b UNIVERSITY OF SASKATCHEWAN   (Canada)

^c DOW AGROSCIENCES LLC   (United States)

Author keywords

Adjuvant; Antibody; Bacterial vector; BHV 1; Bovine IFN ; tgD protein

Indexed keywords

GLYCOPROTEIN D; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G2; IMMUNOGLOBULIN G2 ANTIBODY; IMMUNOLOGICAL ADJUVANT; OIL; PHOSPHATE BUFFERED SALINE; POLY[DI(SODIUM CARBOXYLATOPHENOXY)PHOSPHAZENE]; POLYMER; RECOMBINANT GAMMA INTERFERON; TRUNCATED GLYCOPROTEIN D; UNCLASSIFIED DRUG; WATER;

AMENDED RECOMBINANT CELL; ANIMAL CELL; ARTICLE; BACTERIAL CELL; CATTLE DISEASE; DOSE RESPONSE; DRUG DOSE TITRATION; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; ENCAPSULATION; IMMUNIZATION; INFECTION PREVENTION; INFECTIOUS BOVINE RHINOTRACHEITIS VIRUS; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS FLUORESCENS;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODY FORMATION; CATTLE; CATTLE DISEASES; CLINICAL TRIALS AS TOPIC; FEMALE; HERPESVIRIDAE INFECTIONS; IMMUNIZATION PROGRAMS; INTERFERON-GAMMA; MALE; RECOMBINANT PROTEINS; RECOMBINATION, GENETIC; VARICELLOVIRUS;

EID: 59649101807     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2008.12.049     Document Type: Article

References (40)

1. Huang S., Hendriks W., Althage A., Hemmi S., Bluethmann H., Kamijo R., et al. Immune response in mice that lack the interferon-gamma receptor. Science 259 (1993) 1742-1745
2. Jouanguy E., Lamhamedi-Cherradi S., Lammas D., Dorman S.E., Fondaneche M.C., Dupuis S., et al. A human IFNGR1 small deletion hotspot associated with dominant susceptibility to mycobacterial infection. Nat Genet 21 (1999) 370-378
3. Isaacs A., and Lindermann J. Virus interference. I. The interferon. Proc R Soc Lond B Biol Sci 147 (1957) 258-267
4. Schroder K., Hertzog P.J., Ravasi T., and Hume D.A. Interferon-γ: an overview of signals, mechanisms, and functions. J Leuk Biol 75 (2004) 163-189
5. Tanaka S., Oshima T., Ohsuye K., Ono T., Mizono A., Ueno A., et al. Expression in Escherichia coli of chemically synthesized gene for the human immune interferon. Nucleic Acids Res 11 (1983) 1707-1723
6. Cerretti D.P., McKereghan K., Larsen A., Cosman D., Gillis S., and Baker P.E. Cloning, sequence, and expression of bovine interferon-γ. J Immunol 136 (1986) 4561-4564
7. Hübel K., Dale D.C., and Liles W.C. Therapeutic use of cytokines to modulate phagocytic function and the treatment of infectious diseases: current status of granulocyte colony-stimulating factor, granulocyte-macrophage colony-stimulating factor, macrophage colony-stimulating factor and interferon-γ. J Infect Dis 185 (2002) 1490-1501
8. Bielefeldt O.H., and Babiuk L.A. In vitro and systemic effects of recombinant bovine interferons on natural cell-mediated cytotoxicity in healthy and bovine herpesvirus-1-infected cattle. J Interferon Res 5 (1985) 551-564
9. Raghu G., Brown K.K., Bradford W.Z., Starko K., Noble P.W., Schwartz D.A., et al. A placebo-controlled trial of interferon gamma-1β in patients with idiopathic pulmonary fibrosis. N Engl J Med 350 (2004) 125-133
10. Kleeberg U.R., Suciu S., Brocker E.B., Ruiter D.J., Chartier C., Lienard D., et al. Final results of the EORTC 18871/DKG 80-1 randomised phase III trial. rIFN-alpha2b versus rIFN-gamma versus ISCADOR M versus observation after surgery in melanoma patients with either high-risk primary (thickness > 3 mm) or regional lymph node metastasis. Eur J Cancer 40 (2004) 390-402
11. Kuberski T.T., Servi R.J., and Rubin P.J. Successful treatment of a critically ill patient with disseminated coccidioidomycosis, using adjunctive interferon-gamma. Clin Infect Dis 38 (2004) 910-912
12. Kishko I.H., and Vasylenko M.I. The use of gamma-interferon for the prevention and treatment of infectious diseases in piglets and calves. Mikrobiol Z 61 (1999) 28-32
13. Sordillo L.M., and Babiuk L.A. Controlling acute Escherichia coli mastitis during the periparturient period with recombinant bovine interferon gamma. Vet Microbiol 28 (1991) 189-198
14. Roth J.A., and Frank D.E. Recombinant bovine interferon-gamma as an immunomodulator in dexamethasone-treated and nontreated cattle. J Interferon Res 9 (1989) 143-151
15. Anderson K.P., Fennie E.H., and Yilma T. Enhancement of a secondary antibody response to vesicular stomatitis virus "G" protein by IFN-γ treatment at primary immunization. J Immunol 140 (1988) 3599-3604
16. Yilma T., Owens S., Fennie E.H., and Anderson K.P. Enhancement of primary and secondary immune responses by interferon-gamma. Adv Exp Med Biol 251 (1989) 145-152
17. Vandenbroeck K., Nauwynck H., Vanderpooten A., Van Reeth K., Goddeeris G., and Billiau A. Recombinant porcine IFN-gamma potentiates the secondary IgG and IgA response to an inactivated suid herpesvirus-1 vaccine. J Interferon Cytokine Res 18 (1998) 739-744
18. Raggo C., Habermehl M., Babiuk L.A., and Griebel P. In vivo effects of a recombinant bovine herpesvirus-1 vector expressing bovine interferon-gamma. J Gen Virol 81 (2000) 2665-2673
19. Murray P.J., Aldovini A., and Young R.A. Manipulation and potentiation of antimicrobial immunity using recombinant bacilli Calmette-Guerin strains that secrete cytokines. Proc Natl Acad Sci USA 93 (1996) 934-939
20. Carrier M.J., Chatfield S.N., Dougan G., Nowicka U.T., O'Callaghan D., Beesley J.E., et al. Expression of human IL-1 beta in Salmonella typhimurium. A model system for the delivery of recombinant therapeutic proteins in vivo. J Immunol 148 (1992) 1176-1181
21. al-Ramadi B.K., Adeghate E., Mustafa N., Ponery A.S., and Fernandez-Cabezudo M.J. Cytokine expression by attenuated intracellular bacteria regulates the immune response to infection: the Salmonella model. Mol Immunol 38 (2002) 931-940
22. Steidler L., Robinson K., Chamberlain L., Schofield K.M., Remaut E., Le Page R.W., et al. Mucosal delivery of murine interleukin-2 (IL-2) and IL-6 recombinant strains of Lactococcus lactis co-expressing antigen and cytokine. Infect Immun 66 (1998) 3183-3189
23. Steidler L. In situ delivery of cytokines by genetically engineered Lactococcus lactis. Antonie Van Leeuwenhoek 82 (2002) 323-331
24. Gaertner F.H., Babiuk L.A., Van Moorlehem E.A., Beskorwayne T.K., Lee S.L., Shutter R.W., et al. Amended recombinant cells (ARCs™): an efficient production and delivery vehicle for bovine IFN-γ. J. Controlled Release 107 (2005) 189-202
25. van Drunnen-Little van den Hurk S., Parker M.D., Massie B., Van Den Hurk J.V., Harland R., Babiuk L.A., et al. Protection of cattle from BHV-1 infection by immunization with recombinant glycoprotein IV. Vaccine 11 (1993) 25-33
26. Aguilar J.C., and Rodríguez E.G. Vaccine adjuvants revisited. Vaccine 25 (2007) 3752-3762
27. I interferon on inflammatory responses of bovine phagocytes. J Interferon Res 4 (1984) 249-263
28. Kowalski J., Gilbert S.A., van Drunen Littel-van den Hurk S., van den Hurk J., Babiuk L.A., and Zamb T.J. Heat-shock promoter-friven synthesis of secreted bovine herpesvirus glycoproteins in transfected cells. Vaccine 11 (1993) 1100-1107
29. van Drunen Littel-van den Hurk S., Van Donkersgoed J., Kowalski J., van den Hurk J., Harland R., Babiuk L.A., et al. A subunit gIV vaccine, produced by transfected mammalian cells in culture, induces mucosal immunity against bovine herpesvirus-1 in cattle. Vaccine 2 (1994) 1295-1302
30. Ioannou X.P., Griebel P., Hecker R., Babiuk L.A., and van Drunen Littel-van den Hurk S. The immunogenicity and protective efficacy of bovine herpesvirus 1 glycoprotein D plus Emulsigen are increased by formulation with CpG oligodeoxynucleotides. J Virol 76 (2002) 9002-9010
31. Estes D.M., Closser N.M., and Allen G.K. IFN-gamma stimulates IgG2 production from bovine B cells co-stimulated with anti-mu and mitogen. Cell Immunol 154 (1994) 287-295
32. Cao M., Sasaki O., Yamada A., and Imanishi J. Enhancement of the protective effect of inactivated influenza virus vaccine by cytokines. Vaccine 10 (1992) 238-242
33. Andrianov A.K., Svirkin Y.Y., and LeGolvan M.P. Synthesis and biologically relevant properties of polyphosphazene polyacids. Biomolecules 5 (2004) 1999-2006
34. Mutwiri G., Benjamin P., Soita H., Townsend H., Yost R., Roberts B., et al. Poly[di(sodium carboxylatoethylphenoxy)phosphazene] (PCEP) is a potent enhancer of mixed Th1/Th2 immune responses in mice immunized with influenza virus antigens. Vaccine 25 (2007) 1204-1213
35. Nichani A.K., Kaushik R.S., Mena A., Popowych Y., Dent D., Townsend H.G.G., et al. CpG oligodeoxynucleotide induction of antiviral effector molecules in sheep. Cell Immunol 227 (2004) 24-37
36. Pighetti G.M., and Sordillo L.M. Specific immune responses of dairy cattle after primary inoculation with recombinant bovine interferon-γ as an adjuvant when vaccinating against mastitis. Am J Vet Res 57 (1996) 819-824
37. Mochizuki S., Kobayashi M., Suzuki T., Oikawa A., Koseki T., Nishihara T., et al. Gamma-interferon enhances expression of CD14/MyD88 and subsequent responsiveness to lipopolysaccharide from Actinobacillus actinomycetemcomitans in human gingival fibroblasts. J Periodontal Res 39 (2004) 333-343
38. Landry T.D., Chew L., Davis J.W., Frawley N., Foley H.H., Stelman S.J., et al. Safety evaluation of an α-amylase enzyme preparation derived from archaeal order Thermococcalesas expressed in Pseudomonas fluorescens biovar I. Reg Toxicol Pharmacol 37 (2003) 149-168
39. George S.E., Nelson G.M., Kohan M.J., Brooks L.R., and Boyd C. Colonization and clearance of environmental microbial agents upon intranasal exposure of strain C3H/HeJ mice. Toxicol Environ Health 56 (1999) 419-431
40. Chew L.C., Ramseier T.M., Retallack D.M., Shneider J.C., Squires C.H., and Talbot H.W. Pseudomonas fluorescens. In: Gellissen G. (Ed). Production of recombinant proteins. Novel microbial and eukaryotic expression systems (2005), Wiley-VCH Berlag Bmbh and Co. KGAA, Weinheim 45-65